U.S. Real World Evidence Solutions Market (2026-2036)

Real-world evidence (RWE) is clinical evidence regarding the use and potential benefits or risks of a medical product derived from the analysis of real-world data (RWD). RWD refers to data relating to patient health status and the delivery of healthcare routinely collected from a variety of sources including electronic health records (EHRs), medical claims and billing data, product and disease registries, patient-generated data from digital health technologies, and data gathered through patient surveys. RWE can be produced through various study designs or analyses, including but not limited to observational studies (prospective and retrospective), randomized pragmatic trials, and externally controlled trials. RWE has applications across the pharmaceutical and medical device product life cycle, including drug and device development, regulatory submissions, label expansions, market access and coverage decisions, post-market safety surveillance, and health technology assessment.

The growth of the U.S. RWE solutions market is driven by rapidly growing big data in healthcare, the shift from volume-based to value-based care, the rising focus toward personalized healthcare and precision medicine, and increasing regulatory acceptance of RWE by the U.S. Food and Drug Administration (FDA). Furthermore, the rising adoption of artificial intelligence and machine learning in RWD analysis and the growing integration of genomic data into RWE datasets are expected to offer significant growth opportunities. However, data quality and interoperability challenges across disparate real-world data sources and concerns about data privacy and security remain restraints on market growth.

Real-world evidence solutions include the data assets, software platforms, analytical services, and consulting capabilities that enable life sciences companies, healthcare payers, healthcare providers, regulatory agencies, and other stakeholders to generate, analyze, and apply RWE derived from real-world healthcare data. The U.S. is the largest market for RWE solutions globally, driven by the extensive availability of structured real-world healthcare datasets including medical claims data from commercial insurers, Medicare and Medicaid; EHR data from large integrated health systems and ambulatory networks; specialty pharmacy and specialty distribution data; hospital charge data and chargemaster records; and a growing ecosystem of patient-generated data from wearables, digital health platforms, and decentralized clinical trials.

The FDA has significantly expanded its regulatory framework for RWE since the enactment of the 21st Century Cures Act in December 2016, which required the FDA to issue guidance on the use of RWE in regulatory decision-making. The FDA published final guidance on "Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drug and Biological Products" in August 2023, establishing a framework for evaluating RWE to support new indication approvals or postapproval study requirements for drugs and biologics. In July 2024, the FDA finalized the guidance "Real-World Data: Assessing Electronic Health Records and Medical Claims Data to Support Regulatory Decision-Making for Drug and Biological Products," providing updated recommendations on assessing the relevance and reliability of EHR and claims data for regulatory submissions, while acknowledging emerging technologies such as AI for processing unstructured data. In December 2025, the FDA finalized its updated guidance on the use of RWE to support regulatory decision-making for medical devices, superseding the prior 2017 guidance and providing expanded recommendations aligned with the Food and Drug Omnibus Reform Act of 2022 (FDORA), including detailed considerations for when IDE requirements apply to RWD-based studies.

The FDA’s Advancing RWE Program, a commitment under PDUFA VII enacted as part of the FDA User Fee Reauthorization Act of 2022, provides sponsors with the opportunity to engage with FDA staff during the study planning and design phase to discuss the use of RWE in drug development, including for labeling-supportive evidence generation and post-approval study requirements. The FDA’s Center for Drug Evaluation and Research (CDER) is also tracking regulatory submissions incorporating RWE under PDUFA VII, including new study protocols, final study reports, and NDA and BLA applications containing RWE components from fiscal year 2023 through 2027. These regulatory developments are contributing to increased clarity and confidence among pharmaceutical, biotechnology, and medical device companies seeking to incorporate RWE into regulatory submissions, thereby driving demand for high-quality integrated RWD datasets and advanced RWE analytics services.